Resistance to tobramycin and colistin in isolates of Pseudomonas aeruginosa from chronically colonized patients with cystic fibrosis under antimicrobial treatment

Scandinavian Journal of Infectious Diseases

Volumn 42, Issue 11-12, 2010, Pages 885-889

  Valenza, Giuseppe ^a   Radike, Kerstin ^a   Schoen, Christoph ^a   Horn, Stephan ^a   Oesterlein, Anett ^a   Frosch, Matthias ^a   Abele Horn, Marianne ^a   Hebestreit, Helge ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZTREONAM; BETA LACTAM ANTIBIOTIC; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; MEROPENEM; PIPERACILLIN; TOBRAMYCIN;

AGAR DIFFUSION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIUM ISOLATE; CLINICAL ARTICLE; CYSTIC FIBROSIS; DISEASE EXACERBATION; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR TYPING; NONHUMAN; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION;

ADULT; ANTI-BACTERIAL AGENTS; BACTERIAL TYPING TECHNIQUES; CHRONIC DISEASE; CLUSTER ANALYSIS; COLISTIN; CYSTIC FIBROSIS; DNA FINGERPRINTING; DRUG RESISTANCE, BACTERIAL; FEMALE; GENOTYPE; HUMANS; MALE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TOBRAMYCIN;

EID: 78549268487     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.3109/00365548.2010.509333     Document Type: Article

References (21)

1. Cantón R, Cobos N, de Gracia J, Baquero F, Honorato J, Gartner S, et al. Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fi brosis patients. Clin Microbiol Infect 2005;11: 690-703.
2. Govan JR, Deretic V. Microbial pathogenesis in cystic fi brosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev 1996;60:539-74.
3. Taccetti G, Campana S, Neri AS, Boni V, Festini F. Antibiotic therapy against Pseudomonas aeruginosa in cystic fi brosis. J Chemother 2008;20:166-9.
4. Govan JR. Insights into cystic fi brosis microbiology from the European tobramycin trial in cystic fi brosis. J Cyst Fibros 2002;1:203-8.
5. Wood DM, Smyth AR. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fi brosis. Cochrane Database Syst Rev 2006;(1):CD004197.
6. Frederiksen B, Koch C, Hoiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fi brosis. Pediatr Pulmonol 1997; 23:330-5.
7. Doring G, Hoiby N. Early intervention and prevention of lung disease in cystic fi brosis: a European consensus. J Cyst Fibros 2004;3:67-91.
8. Ratjen F, Doring G. Cystic fi brosis. Lancet 2003;361: 681-9.
9. Moskowitz SM, Silva SJ, Mayer-Hamblett N, Pasta DJ, Mink DR, Mabie JA, et al . Shifting patterns of inhaled antibiotic use in cystic fi brosis. Pediatr Pulmonol 2008;43:874-81.
10. Pitt TL, Sparrow M, Warner M, Stefanidou M. Survey of resistance of Pseudomonas aeruginosa from UK patients with cystic fi brosis to six commonly prescribed antimicrobial agents. Thorax 2003;58:794-6.
11. Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, et al. Intermittent administration of inhaled tobramycin in patients with cystic fi brosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999;340:23-30.
12. Jensen T, Pedersen SS, Garne S, Heilmann C, Hoiby N, Koch C. Colistin inhalation therapy in cystic fi brosis patients with chronic Pseudomonas aeruginosa lung infection. J Antimicrob Chemother 1987;19:831-8. (Pubitemid 17092071)
13. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Twentieth informational supplement. M100-S20, Vol. 30. Wayne, PA: Clinical and Laboratory Standards Institute; 2010.
14. Mahenthiralingam E, Campbell ME, Foster J, Lam JS, Speert DP. Random amplifi ed polymorphic DNA typing of Pseudomonas aeruginosa isolates recovered from patients with cystic fi brosis. J Clin Microbiol 1996;34: 1129-35.
15. UK Cystic Fibrosis Trust Antibiotic Working Group. Antibiotic treatment for cystic fi brosis. 3 rd ed. Bromley, Kent: Cystic Fibrosis Trust; 2009. Available at: http://www.cftrust.org.uk/aboutcf/publications/consensusdoc/ Antibiotic-treatment-for-Cystic-Fibrosis.pdf (accessed July 2010).
16. Flume PA, Mogayzel PJ Jr, Robinson KA, Goss CH, Rosenblatt RL, Kuhn RJ, et al . Cystic fi brosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med 2009;180:802-8.
17. Saiman L, Siegel J. Infection control recommendations for patients with cystic fi brosis: microbiology, important pathogens, and infection control practices to prevent patientto- patient transmission. Infect Control Hosp Epidemiol 2003; 24:S6 - 52.
18. Burns JL, Van Dalfsen JM, Shawar RM, Otto KL, Garber RL, Quan JM, et al . Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial fl ora in patients with cystic fi brosis. J Infect Dis 1999;179: 1190-6.
19. Heijerman H, Westerman E, Conway S, Touw D, Doring G. Inhaled medication and inhalation devices for lung disease in patients with cystic fi brosis: a European consensus. J Cyst Fibros 2009;8:295-315.
20. Morosini MI, Garcia-Castillo M, Loza E, Perez-Vazquez M, Baquero F, Canton R. Breakpoints for predicting Pseudomonas aeruginosa susceptibility to inhaled tobramycin in cystic fi brosis patients: use of high-range Etest strips. J Clin Microbiol 2005;43:4480-5.
21. Johansen HK, Moskowitz SM, Ciofu O, Pressler T, Hoiby N. Spread of colistin resistant non-mucoid Pseudomonas aeruginosa among chronically infected Danish cystic fi brosis patients. J Cyst Fibros 2008;7:391-7.